Related Experiment Video
Updated: May 16, 2025
07:15
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
Published on: July 28, 2020
9.4K
Conference on challenges in sarcoma (CCS) 2024: Expert opinions on non-evidence-based management aspects
Silvia Hofer1, Chantal Pauli2, Beata Bode3
1Institute of Pathology, University Hospital, Zürich, Zürich Switzerland.
European Journal of Cancer (Oxford, England : 1990)
|April 4, 2025
Summary
The 2024 Conference on Challenges in Sarcoma (CCS2024) addressed rare soft tissue sarcomas (STS) and mesenchymal tumors. Experts reached consensus on key diagnostic and therapeutic issues, providing a framework for complex cancer care.
Area of Science:
- Oncology
- Pathology
- Clinical Medicine
Background:
- Soft tissue sarcomas (STS) and mesenchymal tumors are rare, heterogeneous neoplasms with over 150 subtypes, presenting diagnostic and clinical challenges.
- Existing guidelines offer evidence-based procedures, but many clinical scenarios remain controversial in practice.
- The 2024 Conference on Challenges in Sarcoma (CCS2024) convened international experts to address these knowledge gaps.
Purpose of the Study:
- To identify and address controversial issues in the diagnosis and treatment of rare soft tissue sarcomas and mesenchymal tumors.
- To establish consensus among multidisciplinary experts on key clinical decision-making points.
- To provide a framework for managing complex and rare oncological conditions.
Main Methods:
- A Delphi process was employed to identify 200 controversial questions across eight prioritized clinical scenarios.
- Scenarios included tenosynovial giant cell tumor, synovial sarcoma, retroperitoneal sarcomas, angiosarcoma, phyllodes tumor, malignant peripheral nerve sheath tumor, uterine leiomyosarcoma, and atypical lipomatous tumor.
- The 2024 Conference on Challenges in Sarcoma (CCS2024) facilitated discussions among 64 experts.
Main Results:
- Experts discussed 141 controversies during the conference.
- Strong consensus (>90%) was achieved on 24 key diagnostic and therapeutic issues.
- Consensus (>75%) was reached on an additional 45 issues, highlighting areas for future research.
- Unresolved controversies were identified, emphasizing the need for further investigation.
Conclusions:
- The CCS2024 successfully provided a framework for clinical decision-making in sarcoma management.
- The conference underscored the value of consensus-driven approaches for rare and complex malignancies.
- These findings aim to improve the diagnosis and treatment of challenging soft tissue sarcomas and mesenchymal tumors.
